AI Tool Tumor Site Risk Wins FDA Clearance

The FDA has cleared Tumor Site Risk, an AI tool that analyzes existing breast MRI scans to estimate a patient's risk of cancer returning five or ten years after diagnosis. With nearly 400,000 US women diagnosed with breast cancer annually, it helps patients better understand recurrence likelihood.

• Report flags legal risks of AI-generated drug evidence2026-10-21
• Study: AI could cut medical device recalls2026-09-24